Biomolecules involved in alzheimer's disease
AssigneeElectrophoretics Limited
InventorsIan Hugo PIKE, Malcolm Andrew WARD, Claire Louise RUSSELL, Vikram MITRA
Life of this patent
Estimating the term…
Loading patent…
AssigneeElectrophoretics Limited
InventorsIan Hugo PIKE, Malcolm Andrew WARD, Claire Louise RUSSELL, Vikram MITRA
Estimating the term…
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.
1-36. (canceled)
A panel of biomarkers comprising tau or one or more fragments thereof, wherein tau:
A panel of biomarkers comprising a) at least one biomarker selected from Table 5, Table 6, Table 7, Table 8, or Table 9;
Dependencies are inferred from the claim text.